INSMED INC (INSM)
US4576693075 - Common Stock
Relative Strength Alert For Insmed
INSM Makes Notable Cross Below Critical Moving Average
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
Insmed To Present at Three March Conferences
/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
Actress Jane Seymour and Insmed Raise Awareness of "Unseenism" and Empower People to Speak Up When It Comes to Their Health
— New survey reveals the prevalence of "Unseenism," which can be described as a social phenomenon where gender and age biases can leave some patients feeling...
Insmed GAAP EPS of -$1.28 misses by $0.13, revenue of $83.69M beats by $1.08M (NASDAQ:INSM)
Insmed reports Q4 loss, missing EPS estimates by $0.13 but beating revenue expectations by $1.08M.
Interesting INSM Put And Call Options For April 19th
AN2 Therapeutics stock falls as Leerink cuts on trial setback
AN2 Therapeutics (ANTX) shares dropped as Leerink Partners downgraded the company after it paused enrollments in a clinical trial. Read more here.
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
Interesting INSM Put And Call Options For March 15th
Insmed Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
—ARIKAYCE® (amikacin liposome inhalation suspension) Delivers Full-Year 2023 Revenues Exceeding the Upper End of Guidance Range with Unaudited Global Net...
Insmed To Present at the 42nd Annual J.P. Morgan Healthcare Conference
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
Insmed To Present at the Nasdaq 49th Investor Conference
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
JP Morgan bullish on six Big Biotechs, rates nine others neutral or lower (NASDAQ:INSM)
JP Morgan said it was bullish on Insmed (INSM), Denali (DNLI), Immunocore (IMCR), Crinetics (CRNX), Mirum (MIRM) and BioCryst (BCRX), rating all as overweight. Read more here.
First Week of January 2024 Options Trading For Insmed (INSM)
Insmed To Present at Two November Conferences
/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
Insmed Ranks No. 1 on Science's 2023 Top Biopharma Employers List
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
Insmed Non-GAAP EPS of -$1.11 in-line, revenue of $79.07M misses by $0.25M (NASDAQ:INSM)
Insmed reports Q3 non-GAAP EPS in line with expectations, but revenue misses by $0.25M. ARIKAYCE total revenue for Q3 reflects highest sales since launch.
Insmed Reports Third-Quarter 2023 Financial Results and Provides Business Update
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $79.1 Million for the Third Quarter of 2023 Reflects Highest Quarter of Sales Since...
Noteworthy Wednesday Option Activity: AFRM, MDB, INSM
Insmed to Host Third-Quarter 2023 Financial Results Conference Call on Thursday, October 26, 2023
/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
Why Shares of Insmed Are Soaring This Week
The biotech company announced positive top-line trial results and received upgrades from analysts.
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
Insmed Is Making A Comeback — Why Shares Hit A Year High In Colossal Volume
The company is working on a treatment for a bacterial lung infection.
Why Insmed Stock Is Soaring Today
Investors applauded the company's latest clinical results.
Insmed stock gains as antibiotic succeeds in Phase 3 trial
Insmed Incorporated (INSM) said Tuesday a Phase 3 trial for its antibiotic Arikayce reached succeeded in adults with a type of bacterial lung infection. Read more here.
Noteworthy Wednesday Option Activity: HELE, BURL, INSM